Imugene Limited has received a $5.87 million R&D tax refund, reinforcing its capacity to advance clinical trials in immuno-oncology. This funding milestone supports the development of its innovative cancer therapies, including CAR T cell treatments and oncolytic virotherapy.
Barton Gold has secured a $2.4 million R&D tax refund for FY2024, significantly enhancing its cash reserves and accelerating its exploration programs in South Australia’s emerging gold province.
